Achillion (ACHN) Reports Wider-than-Expected Loss In Q1
Zacks Investment Research | May 08, 2017 02:01AM ET
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) reported a loss of 15 cents per share in the first quarter, wider than the Zacks Consensus Estimate of a loss of 8 cents. In the year-ago quarter, the company had reported a loss of 13 cents per share.
The company generated no revenues in the reported quarter. The company also had no revenues in the year-ago quarter.
Shares of Achillion gained almost 7.8% on May 5, in spite of the company reporting wider-than-expected loss for the first quarter of 2017 a day before. However, the stock has underperformed the Zacks classified Medical-Biomed/Genetics industry year to date. The company’s shares lost 10.2% whereas the industry registered an increase of 3.9%.
Research and development expenses increased 16.5% from the year-ago period to $15.5 million due to increased clinical trial and consulting costs related to pipeline candidate ACH-4471. The increase in expenses also included preclinical and manufacturing costs related to next generation factor D inhibitor compounds in development.
General and administrative expenses were up 5.56% to $5.7 million due to an increase in corporate legal fees and consulting fees.
Pipeline Update
During the quarter, Achillion was granted a patent to compositions of matter for compounds that inhibit complement factor D activity. Also, U.S. Patent and Trademark Office (USPTO) issued notices of allowance of four additional U.S. patent applications owned by Achillion, which are expected to be issued as patents over the next few months.
The company initiated a phase II study evaluating its key pipeline candidate, a factor D inhibitor, ACH-4471 for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). Subsequent to the quarter, in April, Achillion initiated patient dosing in the phase II study of ACH-4471 and recently completed 28 days of dosing. The patients will receive up to two additional months of therapy. The company plans to present interim results in a future medical conference
Also, Achillion announced additional results from Johnson & Johnson’s (NYSE:JNJ) Janssen-sponsored phase II study. The data demonstrated that the triple combination of simeprevir, odalasvir and AL-335 has the ability to shorten treatment duration in patients whose disease is caused by hepatitis C virus (HCV) genotype 1 (GT1).
Get The News You Want
Achillion Pharmaceuticals, Inc. Quote
Zacks Rank & Key Picks
Achillion currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector include BioTime, Inc. (NYSE:BTX) and Celsion Corp. (NASDAQ:CLSN) . Each of these stock carries a Zacks Rank #2 (Buy). You can see .
BioTime’s loss estimates narrowed 60.9% over the last 60 days to 18 cents for 2017. The company posted a positive earnings surprise in two of the four trailing quarters with an average beat of 12.32%. Its shares have increased 10.3% in the last one year.
Celsion’s loss estimates narrowed 42.9% to 28 cents for 2017 over the last 60 days. The company posted a positive earnings surprise in two of the four trailing quarters with an average beat of 0.24%.
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.